A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
25
11
2020
accepted:
15
02
2021
pubmed:
21
4
2021
medline:
15
12
2021
entrez:
20
4
2021
Statut:
ppublish
Résumé
Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms. This was a phase 2, randomized, open-label, 16-week, treat-to-target study. Insulin-naive adults ( TIR improved from baseline (means: A, 57.0%; B, 55.2%; C, 51.0%; IGlar U100, 55.3%) to weeks 15 and 16 (estimated mean: A, 76.6%; B, 83.0%; C, 80.9%; IGlar U100, 75.9%). TIR was greater for titration B than for IGlar U100 (estimated treatment difference 7.08%-points; 95% CI 2.12 to 12.04; Once-weekly icodec was efficacious and well tolerated across all three titration algorithms investigated. The results for icodec titration A (80-130 mg/dL; ±21 units/week) displayed the best balance between glycemic control and risk of hypoglycemia.
Identifiants
pubmed: 33875484
pii: dc20-2878
doi: 10.2337/dc20-2878
pmc: PMC8323172
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin, Long-Acting
0
insulin icodec
0
Insulin Glargine
2ZM8CX04RZ
Banques de données
ClinicalTrials.gov
['NCT03951805']
figshare
['10.2337/figshare.14054921']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1595-1603Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK124723
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002489
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by the American Diabetes Association.
Références
Diabetes Care. 2019 Mar;42(3):400-405
pubmed: 30352896
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
J Diabetes Sci Technol. 2019 Jul;13(4):614-626
pubmed: 30636519
Diabetes Technol Ther. 2019 Feb;21(2):81-85
pubmed: 30575414
Diabetes Care. 2020 Nov;43(11):2882-2885
pubmed: 32887707
Diabetes Care. 2005 Nov;28(11):2673-9
pubmed: 16249538
Diabetes Obes Metab. 2019 Apr;21(4):920-929
pubmed: 30520248
Patient Prefer Adherence. 2016 Jul 22;10:1299-307
pubmed: 27524885
Diabetes Care. 2021 Feb;44(2):549-555
pubmed: 33097560
Diabetes Obes Metab. 2019 Oct;21(10):2203-2210
pubmed: 31168921
J Diabetes Res. 2020 Feb 6;2020:5817074
pubmed: 32090120
Diabetes Ther. 2018 Jun;9(3):1099-1111
pubmed: 29644618
Adv Ther. 2017 Mar;34(3):658-673
pubmed: 28078541
BMJ Open Diabetes Res Care. 2020 Jan;8(1):
pubmed: 31958307
Diabetes Obes Metab. 2013 Feb;15(2):175-84
pubmed: 23130654
Diabetes Care. 2010 Jun;33(6):1176-8
pubmed: 20200301
Diabet Med. 2009 Jul;26(7):722-8
pubmed: 19573122
Diabetes Care. 2018 Nov;41(11):2370-2376
pubmed: 30201847
Diabetologia. 2008 Mar;51(3):408-16
pubmed: 18204830
Diabetes Spectr. 2016 Aug;29(3):166-70
pubmed: 27574371
Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64
pubmed: 29222377
N Engl J Med. 2020 Nov 26;383(22):2107-2116
pubmed: 32960514
Metabolism. 2020 May;106:154190
pubmed: 32109448
Diabetes Obes Metab. 2011 Feb;13(2):144-9
pubmed: 21199266
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Diabetes Technol Ther. 2020 Feb;22(2):72-78
pubmed: 31524497